Recent Blog Articles
HIV rates rising: Could new forms of PrEP help?
Careful! Scary health news can be harmful to your health
Post-pandemic weight loss: There’s an app for that
Cognitive behavioral therapy for insomnia by telemedicine: Is it as good as in-person treatment?
Prediabetes diagnosis as an older adult: What does it really mean?
Is blood sugar monitoring without diabetes worthwhile?
Large review study finds low risk of erectile dysfunction after prostate biopsy
Does exercise help protect against severe COVID-19?
A new Alzheimer’s drug has been approved. But should you take it?
Need physical therapy? 3 key questions your PT will ask
In the news: FDA approves one drug for irritable bowel syndrome but suspends another
In the news
FDA approves one drug for irritable bowel syndrome but suspends another
Irritable bowel syndrome (IBS) is a chronic condition characterized by recurrent bouts of constipation or diarrhea (or both, alternating), abdominal pain, gas, and bloating. It's a functional disorder — that is, one that isn't attributable to any underlying disease or structural abnormality. Though there's no cure, there are many treatment methods that vary depending on the predominant symptoms. Several medications are available, but the prescription drugs approved for IBS have had a checkered history.
In April 2008, the FDA approved Amitiza (lubiprostone) for use in women ages 18 or over who have constipation-predominant IBS (IBS-C). Amitiza, which belongs to a class of drugs called prostones, is now the only widely available prescription medication for IBS-C. In March 2007, another IBS-C drug, Zelnorm (tegaserod), was taken off the market because of a slightly increased risk for heart attack, angina, and stroke. It came back in July 2007 under a special program that made it available to women under age 55 for whom nothing else worked. But in March 2008, the program was suspended by Zelnorm's manufacturer, Novartis Pharmaceuticals. Now, the drug can be used only in life-threatening situations or when hospitalization is necessary.
To continue reading this article, you must log in.
Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.
- Research health conditions
- Check your symptoms
- Prepare for a doctor's visit or test
- Find the best treatments and procedures for you
- Explore options for better nutrition and exercise
I'd like to receive access to Harvard Health Online for only $4.99 a month.Sign Me Up
Already a member? Login ».
As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles. No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.